Optimal salvage therapy for primary refractory peripheral T-cell lymphomas (PTCL) and the role of hematopoietic stem cell transplant (SCT) remain poorly defined. We conducted a retrospective review of clinical outcomes and prognostic factors in a single-center cohort of 93 patients with primary refractory PTCL, defined as progression during first-line therapy or relapse within 6 months of its completion. Clinical outcomes were poor in this population, with median event-free survival (EFS) of 3.5 months, median overall survival (OS) of 9.1 months, and 34% 3-year survival. Outcomes were comparable in patients who progressed through first-line therapy and patients who achieved CR/PR and subsequently relapsed within 6 months. A majority exhibited high-risk features and had intermediate to high risk IPI, which correlated with inferior outcomes. There was no difference in outcomes between patients who received single-agent salvage regimens and patients who underwent traditional, multi-agent salvage regimens. Thus, participation in well-designed clinical trials should be encouraged in this population. Additionally, there may be a trend toward improved EFS and OS in patients who underwent autologous or allogeneic SCT compared to patients who achieved CR or PR but were not transplanted.
| I N TR ODU C TI ON
Peripheral T-cell lymphoma (PTCL) accounts for 10%-15% of all nonHodgkin's lymphomas and 15%-20% of aggressive lymphomas in western countries. 1 Despite anthracycline-based front-line treatment (usually CHOP or CHOEP), only a minority (30%) of patients with the most common PTCL subtypes achieve a durable remission and longterm disease-free survival. [1] [2] [3] Although response rates and outcomes with currently available salvage therapies are poor, response to initial therapy is predictive of improved survival. 4 Primary refractory disease and early relapse upon completion of initial therapy are not uncommon.
For example, the Nordic Lymphoma Group prospectively examined the role of dose-dense induction therapy consolidated with high-dose therapy and autologous stem-cell transplantation in first remission. 5 Among evaluable patients enrolled, primary refractory disease was observed in 16% and early relapse (within two years of treatment), presumably secondary to chemotherapy resistant minimal residual disease, was observed in 18%.
Front-line therapy for PTCL is largely extrapolated from the experience in management of aggressive B-cell NHL, most commonly anthracycline-based multi-drug regimens (e.g., CHOP, CHOEP). Similarly, conventional salvage regimens (e.g., ICE, DHAP) are widely utilized in the management of primary refractory or relapsed disease, particularly in fit or transplant eligible patients. Unfortunately, complete and durable response rates are disappointingly low with these regimens. 2, 3 In a cohort of 153 patients from British Columbia with relapsed or refractory PTCL after initial therapy, 26% achieved a complete remission with salvage therapy, with a median overall survival (OS) of 5.5 months and median progression-free survival of 3.1 months after failing first line therapy. 2 Similarly, Briski et al. described eventfree survival of 3 months and OS of 6 months in relapsed/refractory PTCL patients with stage III or IV disease, and in all relapsed/refractory patients who did not undergo hematopoietic stem cell transplant. 3 Novel agents, including the novel antifolate pralatrexate, 6 the HDAC inhibitors romidepsin [7] [8] [9] and belinostat, 10, 11 and brentuximab vedotin, [12] [13] [14] have been approved for the treatment of relapsed/refractory PTCL. With few exceptions, complete and durable responses are rarely achieved with these novel agents. The optimal sequencing of either conventional or novel agents, and the role of either autologous or allogeneic stem cell transplantation, particularly in the setting of Other histologies include extranodal NK/T-cell lymphoma (n 5 6), hepatosplenic T-cell lymphoma (n 5 2), and enteropathy-associated T-cell lymphoma (n 5 4). Includes patients treated with local radiation alone, steroids alone, or observation/supportive care, as well as patients with unknown salvage therapy status.
(cyclophosphamide, doxorubicin, vincristine, prednisone, 1/-etoposide) as their first-line therapy. In this cohort with primary refractory disease, most patients (63%) received a conventional multiagent salvage regimen (most commonly ICE), and 16% received alternative, single-agent systemic therapies, including gemcitabine monotherapy, retinoids, pralatrexate, denileukin diftitox, the proteasome inhibitor ixazomib, brentuximab vedotin, the histone deacetylase inhibitor romidepsin, and cyclosporine. Twenty percent received local radiation, corticosteroids, supportive care, or had unknown salvage treatment status ( Table 1) .
As expected, clinical outcomes in primary refractory PTCL were generally poor. Sixty-nine events and 55 deaths were observed in our cohort. The median EFS after relapse/progression on first-line therapy When only PTCL, NOS and AITL cases were included, EFS (progression: median 3.1 months v. relapse: 5.4 months; P 5 .9) and OS (7.3 v.
9.2 months; P 5 .8) were comparable between these groups as well.
Therefore, these subpopulations were combined as one cohort in further analyses.
The IPI at time of relapse or progression was prognostic in patients with primary refractory PTCL, and patients with higher risk IPI scores had progressively inferior EFS and OS (Supporting Information Figure   S2A ,B). Similar trends were observed when this analysis was confined to only patients receiving salvage therapies (Supporting Information Figure   S2C ,D), and when patients were stratified by PIT (Supporting Information Figure S2E ,F). The prognostic significance of the components of the IPI and PIT at time of relapse or progression, which include age, Eastern
Cooperative Oncology Group (ECOG) performance status, LDH, Ann
Arbor stage, number of extranodal sites, and bone marrow involvement,
were assessed on univariate analysis. Age greater than 60 years and elevated LDH were associated with inferior OS (P 5 .03 and .0003 respectively) (Supporting Information Table S1 ). On multivariate analysis with age, LDH, and number of extranodal sites as prognostic factors for OS, only elevated LDH was associated with inferior OS (P 5 .0008).
Single-agent salvage regimens showed no difference in EFS or OS 
| D ISC USSION
In contrast to previous studies describing the natural history of relapsed/refractory PTCL, 2,3 we sought to investigate outcomes in were not transplanted, although this was not statistically significant.
The observation that novel agents and single-agent therapies achieved outcomes comparable to traditional and more intense regimens (e.g., ICE, DHAP) in our cohort, despite older age and more frequent BM involvement in the single-agent group (Supporting Information Table   S2A ), supports current recommendations encouraging participation in well-designed clinical trials among patients with primary refractory PTCL. Our findings are similar to findings from a cohort of 1020 cases of refractory and relapsed PTCL prospectively collected through the international T-Cell Project, in which median OS was 5.8 months and 3-year OS was 21% in the primary refractory setting, and auto-SCT was associated with improved outcomes. 15 The mechanisms of chemotherapy resistance and the inferior outcomes we observed are poorly understood. For example, IDH-mutated AITL is characterized by global DNA hypermethylation and downregulation of various tumor suppressor genes, including negative regulators of T-cell receptor (TCR) signaling. 16 Conversely, activating mutations in signaling intermediates required for TCR signaling (e.g., PLC-g1, PI3K, or CARD11) are recurrently observed in AITL 17 and in other T-cell malignancies. 18 The genetic landscape in AITL, particularly evidence implicating a pathogenic role for TCR engagement, is consistent with Among patients with relapsed and refractory PTCL, particularly those who failed autologous SCT, allogeneic SCT remains a viable option to achieve durable remission. 25 Our study suggests that patients who undergo SCT (of any type) may have improved survival compared to those who also achieve a remission with salvage therapy but never undergo SCT. Of course, this contention is tentative, as the limited sample size in our cohort precludes a definitive conclusion, and there may be fundamental clinical differences between non-transplanted and transplanted patients (e.g., older age, more aggressive disease; Supporting Information Table S2B ). Nonetheless, our findings align with current recommendations for the use of autologous and allogeneic SCT for consolidation in transplant eligible patients with chemotherapy-sensitive disease. In addition, our study is also limited by its retrospective nature, including provider assessments of disease response, and a paucity of patients treated with recently approved novel, or investigational, agents.
In summary, this cohort of 93 patients with primary refractory PTCL is one of the largest reported in the literature, and as such, may provide a useful benchmark for future studies and clinical trials including patients with primary refractory PTCL. Most long-term disease-free survivors in this cohort had undergone high dose therapy and auto-SCT or allo-SCT, which are currently recommended consolidation strategies among patients with chemo-sensitive disease. We were unable to discern a significant difference in outcomes between traditional, multi-agent salvage regimens compared to novel, single-agent regimens in this cohort. This supports current recommendations for patients with relapsed/refractory PTCL to participate in rational and well-designed clinical trials.
